马颖艳,王艳霞,徐白鸽,李娜,黄光华,王彩莲,方毅,韩雅玲

• 1:沈阳军区总医院心血管病研究所
• 2:心血管内科

摘要(Abstract)：

目的观察替格瑞洛用于经皮冠状动脉介入治疗(PCI)患者抗血小板治疗的有效性和安全性。方法选择50例冠心病PCI术后应用氯吡格雷抗血小板,因血小板聚集率不达标且CYP2C19基因异常而改用替格瑞洛的患者。所有入选患者应用阿司匹林首次负荷剂量300 mg,维持剂量100 mg,每日一次;替格瑞洛维持剂量90 mg,每日二次,持续1年。研究主要终点为随访1个月的主要不良心血管事件(包括死亡、支架内血栓形成、支架内再狭窄、非致死性心肌梗死、靶血管血运重建)和脑卒中的发生率;次要终点为一般不良事件(包括轻微出血、过敏、呼吸困难)的发生率及血小板计数的变化情况。结果患者应用替格瑞洛后随访1个月未出现主要不良心血管事件和脑卒中;一般不良事件的发生率较低,2例(4%)出现呼吸困难,2例(4%)发生轻微出血,其中1例鼻出血,1例皮下淤血。应用替格瑞洛后血小板聚集率明显低于氯吡格雷,血小板计数未明显下降。结论替格瑞洛用于存在氯吡格雷抵抗的PCI患者抗血小板治疗,短期内安全有效。

关键词(KeyWords)： 支架术;经皮冠状动脉介入治疗;替格瑞洛

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 马颖艳,王艳霞,徐白鸽,李娜,黄光华,王彩莲,方毅,韩雅玲

参考文献(References)：

• [1]Aronow WS.Antiplatelet therapy in the treatment of atherothrombotic disease:considering the evidence.Geriatrics,2007,62:12-24.
• [2]Fares RR,Lansing LS,Gallati CA,et al.Antiplatelet therapy with clopidogrel and aspirin in vascular diseases:clinical evidence for and against the combination.Expert Opin Pharmacother,2008,9:377-386.
• [3]阮长耿.抗血小板药物研制与临床应用进展.中国药房,2013,24:3553-3555.
• [4]Rivera J,Lozano ML,Navarro-Núez L,et al.,Platelet receptors and signaling in the dynamics of thrombus formation.Haematologica,2009,94:700-711.
• [5]Yusuf S,Zhao F,Mehta SR,et al.Effects of clopidogrel inaddition to aspirin in patients with acute coronary syndromes without STsegment elevation:the Clopidogrel in Unstable Angina to Prevent recurrent Events Trial Investigators.N Engl J Med,2001,345:494-502.
• [6]Abergel E,Nikolsky E.Ticagrelor:an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.Vasc Health Risk Manag,2010,6:963-977.
• [7]Pettersen AA,Arnesen H,Opstad TB,et al.The influence of CYP2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel.Thromb J,2011,9:4.
• [8]Tantry US,Bliden KP,Wei C,et al.First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel the ONSET/OFFSET and RESPOND genotype studies.Circ Cardiovasc Genet,2010,3:556-566.
• [9]Gurbel PA,Bliden KP,Butler K,et al.Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease the ONSET/OFFSET study.Circulation,2009,120:2577-2585.
• [10]Gurbel PA,Bliden KP,Butler K,et al.Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies the RESPOND study.Circulation,2010,121:1188-1199.
• [11]Wallentin L,Becker RC,Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes.N Engl J Med,2009,361:1045-1057.
• [12]James S,Akerblom A,Cannon CP,et al.Comparison of ticagrelor,the first reversible oral P2Y(12)receptor antagonist,with clopidogrel in patients with acute coronary syndromes:Rationale,design,and baseline characteristics of the PLATelet inhibition and patient Outcomes(PLATO)trial.Am Heart J,2009.157:599-605.
• [13]Cannon CP,Harrington RA,James S,et al.Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes(PLATO):a randomised double-blind study.Lancet,2010,375:283-293.
• [14]朱永宏,贾国良,周妙,等.替格瑞洛治疗41例急性冠状动脉综合征患者的临床疗效.中国介入心脏病学杂志,2013,21:374-376.
• [15]2012 Writing Committee Members,Jneid H,Anderson JL,et al.2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non–ST-elevation myocardial infarction(updating the 2007 guideline and replacing the2011 focused update)a report of the american college of cardiology foundation/American heart association task force on practice guidelines.Circulation,2012,126:875-910.